

**Van:** [ccmo\\_bi](mailto:ccmo_bi)  
**Aan:** [ccmo\\_frontoffice](mailto:ccmo_frontoffice); [ccmo\\_eudract](mailto:ccmo_eudract)  
**Onderwerp:** FW: NL61015.029.17 - CCNP520A2202J -Declaration of Local and Global end of trial  
**Datum:** woensdag 18 maart 2020 12:21:35  
**Bijlagen:** [A1 CCNP520A2202J Cover Letter NL61015.029.17 18Mar2020.pdf](#)  
[B7 CCNP520A2202J Declaration of the End of Trial form –Annex III 18Mar2020.pdf](#)

---

Einde studie NL voor Marjolein.

Groet, 5.1.2.e

---

**Van:** 5.1.2.e <5.1.2.e@novartis.com> Namens 5.1.2.e  
**Verzonden:** woensdag 18 maart 2020 12:21  
**Aan:** ccmo\_bi <bi@ccmo.nl>  
**Onderwerp:** NL61015.029.17 - CCNP520A2202J -Declaration of Local and Global end of trial

Dear Madam, dear Sir,

On behalf of the Sponsor, Novartis Pharma AG, PAREXEL International Romania s.r.l. herewith notifies the local and global end of the above-mentioned clinical trial.

The Last Patient Last Visit (LPLV) for the study CCNP520A2202J was achieved globally on 13-Mar-2020.

The end of trial in The Netherlands was achieved on 10-Mar-2020.

Please find attached the Cover letter and the Declaration of the end of trial form for this notification.

We trust that the information provided in the application is sufficient, however if you require any further information, please contact us.

Yours faithfully,

**PAREXEL International Romania s.r.l.**

5.1.2.e on behalf of 5.1.2.e

Metropolis Center, 89-97 Grigore Alexandrescu Street  
Bucharest, Romania, 010624

Tel: +403 5.1.2.e

Fax: +40 372 5.1.2.e

E-mail: 5.1.2.e [@novartis.com](mailto:5.1.2.e@novartis.com)